ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia-Reference-Cited by-同舟云学术

ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

Published:2015-09-01 Issue: Volume: Page:ehv370
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:Eur Heart J

Author:

Kastelein John J.P.,Ginsberg Henry N.,Langslet Gisle,Hovingh G. Kees,Ceska Richard,Dufour Robert,Blom Dirk,Civeira Fernando,Krempf Michel,Lorenzato Christelle,Zhao Jian,Pordy Robert,Baccara-Dinet Marie T.,Gipe Daniel A.,Geiger Mary Jane,Farnier Michel

Publisher

Oxford University Press (OUP)

Subject

Cardiology and Cardiovascular Medicine

Link

http://academic.oup.com/eurheartj/article-pdf/36/43/2996/17355813/ehv370.pdf

Reference18 articles.

1. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

2. Risk of fatal coronary heart disease in familial hypercholesterolaemia. Scientific Steering Committee on behalf of the Simon Broome Register Group.

3. Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management

4. Two Years after Molecular Diagnosis of Familial Hypercholesterolemia: Majority on Cholesterol-Lowering Treatment but a Minority Reaches Treatment Goal

5. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands

Cited by 475 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The therapeutic effect of PCSK9 inhibitors on dyslipidemia: one-year follow up;European Journal of Translational Myology;2024-09-13

2. Lipid Disorders and Pregnancy;Endocrinology and Metabolism Clinics of North America;2024-09

3. Interaction Between Primary Hyperlipidemias and Type 2 Diabetes: Therapeutic Implications;Diabetes Therapy;2024-07-30

4. Impact of PCSK9 Inhibitors on Lipoprotein(a): A Meta-analysis and Meta-regression of Randomized Controlled Trials;2024-07-11

5. PCSK9 Inhibitors and Infection-Related Adverse Events: A Pharmacovigilance Study Using the World Health Organization VigiBase;Drugs - Real World Outcomes;2024-07-02